Artikel mit Open-Access-Mandaten - Alexander EGGERMONTWeitere Informationen
Nicht verfügbar: 10
Prüfen
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
Mandate: National Institute of Health and Medical Research, France
Prüfen
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
L Boussemart, H Malka-Mahieu, I Girault, D Allard, O Hemmingsson, ...
Nature 513 (7516), 105-109, 2014
Mandate: Swiss Cancer League
Prüfen
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
SS Agarwala, U Keilholz, E Gilles, AY Bedikian, J Wu, R Kay, CA Stein, ...
European Journal of Cancer 45 (10), 1807-1814, 2009
Mandate: US National Institutes of Health
Prüfen
Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status
Y Messai, S Gad, MZ Noman, G Le Teuff, S Couve, B Janji, SF Kammerer, ...
European urology 70 (4), 623-632, 2016
Mandate: Cancer Research UK, National Institute for Health Research, UK
Prüfen
Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial
C Jovelet, E Ileana, MC Le Deley, N Motté, S Rosellini, A Romero, ...
Clinical Cancer Research 22 (12), 2960-2968, 2016
Mandate: National Institute of Health and Medical Research, France
Prüfen
Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model
LRC Pedrosa, O van Tellingen, T Soullié, AL Seynhaeve, ...
European Journal of Pharmaceutics and Biopharmaceutics 94, 207-219, 2015
Mandate: Dutch Cancer Society
Prüfen
Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?
B Baroudjian, L Boussemart, E Routier, B Dreno, Y Tao, E Deutsch, ...
European Journal of Dermatology 24 (2), 265-267, 2014
Mandate: National Institute of Health and Medical Research, France
Prüfen
European academy of cancer sciences—designation of comprehensive cancer centres of excellence
U Ringborg, J Celis, A Eggermont, A Berns
European Journal of Cancer 93, 138-139, 2018
Mandate: US National Institutes of Health
Prüfen
The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model
AMM Eggermont, D Bellomo, J Dwarkasing, L Meerstein-Kessel, A Meves
European Journal of Cancer 157, 518-519, 2021
Mandate: US National Institutes of Health
Prüfen
The Virtual Child
RJ Gilbertson, S Behjati, AL Böttcher, ME Bronner, M Burridge, ...
Cancer Discovery 14 (4), 663-668, 2024
Mandate: Cancer Research UK, Brain Tumour Charity, UK
Verfügbar: 117
Prüfen
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
Mandate: US National Institutes of Health
Prüfen
Final version of 2009 AJCC melanoma staging and classification
CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ...
Journal of clinical oncology 27 (36), 6199-6206, 2009
Mandate: US National Institutes of Health
Prüfen
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
Mandate: European Commission, Swiss Cancer League, Leducq Foundation, USA
Prüfen
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ...
Science 350 (6264), 1079-1084, 2015
Mandate: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung …
Prüfen
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
Mandate: US National Institutes of Health, National Health and Medical Research …
Prüfen
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
Mandate: US National Institutes of Health
Prüfen
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
New England Journal of Medicine 375 (19), 1845-1855, 2016
Mandate: US National Institutes of Health
Prüfen
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
The lancet oncology 16 (5), 522-530, 2015
Mandate: US National Institutes of Health
Prüfen
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
Mandate: US National Institutes of Health, National Health and Medical Research …
Prüfen
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N Chaput, P Lepage, C Coutzac, E Soularue, K Le Roux, C Monot, ...
Annals of Oncology 28 (6), 1368-1379, 2017
Mandate: National Institute of Health and Medical Research, France
Angaben zur Publikation und Finanzierung werden automatisch von einem Computerprogramm ermittelt